Hansoh Pharmaceutical Group Co Ltd (3692.xhkg) is a Chinese research and development pharmaceutical company headquartered in Shanghai, the People’s Republic of China. Hansoh Pharmaceutical engages in researching, developing, manufacturing, and commercialising of innovative drugs. Hansoh mainly focuses in serious diseases and disorders, including oncology, central nervous system (CNS) disorders, infectious diseases, cardiovascular diseases, leukemia, diabetes, and autoimmune diseases. Hansoh Pharmaceutical Group has more than 10,000 employees in China and the United States, and over 1,600 highly skilled research and development professionals across two locations in Lianyungang and Zhangjiang, China. The Chinese pharmaceutical has activities not only in China, but also in Taiwan, Hong Kong and Macau. Hansoh Pharmaceutical Group Co Ltd stock(3692.xhkg) is traded on the Hong Kong Stock Exchange (SEHK), has a $10.51B (HKD) market cap as of November 2021 and $10,61B (HKD) in 2020 yearly revenue. On 12 October 2021, Hansoh Pharmaceutical Group Co Ltd (3692.xhkg) has entered into Licensing and Collaboration Agreement with South Korean OilX Pharmaceuticals to develop and commencialize siRNA Therapeutics in China.
Hansoh Pharmaceutical Group Co Ltd (3692.xhkg): Trade a Contract for Difference (CFD) on 3692.xhkg and speculate on the share price difference of the underlying asset. CFD is a financial contract that allows you to trade on the underlying asset value (share price) without the need to purchase the actual stock. Investors are trading the difference in the value of security between the opening and closing of the trade. You can either hold a long position (Buy) or a short position (Sell). CFDs are considered short-term investments or trades, as CFDs tend to be used within shorter timeframes.
Hansoh Pharmaceutical Group Co Ltd (3692)
Explore Hansoh Pharmaceutical Group Co Ltd (3692) share trends and insights to improve your trading decisions. Stay informed with FP Markets Bangladesh.